We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NCE

News List

Formulation development of New chemical Entities (NCE’s) to commercialization Deepak Hegde
June 16, 2021
The process of taking a new drug from concept to clinic and eventually to commercialization involves several steps which traditionally occur in series.
Tris Pharma® Acquires Park Therapeutics americanpharmaceuticalreview
April 30, 2021
Tris Pharma, Inc., a specialty pharmaceutical company with a portfolio of approved products and a late-stage pipeline of product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related conditions, has acquired Park ...
ISSAR Pharma announces out-licensing of its peptide-based NCEs expresspharma
April 21, 2021
ISSAR has several patents for peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology and diseases of bones and joints.
Vyera to Initiate Phase 1 Study of NCE for Toxoplasmosis biospectrumasia
November 20, 2018
The letter from the FDA gives permission for Vyera to proceed with dosing human subjects in its Phase 1 SAD study of VYR-006.